Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 3/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 5/20 | 0.55 |
| ▸ | BRD4 | O60885 | 11/20 | 0.54 |
| ▸ | JAK1 | P23458 | 5/20 | 0.54 |
| ▸ | JAK3 | P52333 | 4/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.54 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.54 |
| ▸ | BRD2 | P25440 | 2/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | SIK1 | P57059 | 1/20 | 0.51 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.51 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576163 | 0.88 | TNK2 (0.58) | AXLFLT3JAK2BRD4JAK3 | |
| SCHEMBL29576049 | 0.87 | HTR3A (0.50) | AXLFLT3BTKJAK2BRD4 | |
| SCHEMBL29576129 | 0.86 | MAP4K1 (0.53) | AXLFLT3BTKBRD4MAP4K1 | |
| SCHEMBL29576376 | 0.85 | WEE1 (0.60) | FLT3JAK2BRD4JAK1JAK3 | |
| SCHEMBL29576910 | 0.85 | PAK1 (0.57) | AXLFLT3JAK2BRD4JAK1 | |
| SCHEMBL30515551 | 0.82 | MAP4K1 (0.50) | AXLFLT3BTKJAK2JAK3 | |
| SCHEMBL27174693 | 0.81 | MAP4K1 (0.73) | JAK2JAK1JAK3MAP4K1CDK4 | |
| SCHEMBL29576362 | 0.81 | HTR3A (0.51) | AXLFLT3BTKBRD4JAK1 | |
| SCHEMBL29368254 | 0.81 | MAP4K1 (0.60) | FLT3JAK2BRD4JAK1JAK3 | |
| SCHEMBL29576526 | 0.79 | WEE1 (0.56) | JAK2JAK1JAK3MAP4K1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | AXL 716/4885FLT3 210/4885BTK 317/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | AXL 716/4885FLT3 210/4885BTK 317/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | AXL 716/4885FLT3 210/4885BTK 317/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | AXL 716/4885FLT3 210/4885BTK 317/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | AXL 716/4885FLT3 210/4885BTK 317/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | AXL 444/4885FLT3 11/4885BTK 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.